5 Nuclear Hematology Kshitish C

Total Page:16

File Type:pdf, Size:1020Kb

5 Nuclear Hematology Kshitish C Chapter 5 5 Nuclear Hematology Kshitish C. Das 5.1 Introduction 90 5.26.2 Bone Marrow Imaging by Scintigraphy 126 5.26.3 Leukocyte (WBC) or Granulocyte Labeling for 5.2 Hematopoiesis and Hematopoietic Tissues 91 Imaging Bone Marrow 127 5.3 The Sites and Distribution of Prenatal and 5.26.4 Blood Platelets 127 Postnatal Hematopoietic Tissue 96 5.26.5 Measurement of Platelet Survival 128 5.4 Hematopoietic Growth Factors 97 References 128 5.5 Hematopoiesis and Hematopoietic Stem Cells 98 5.6 Hematopoietic Cell Lineages 99 5.7 Erythropoiesis 100 5.1 5.8 Globin Chain Synthesis 100 Introduction 5.9 Heme Synthesis 101 Nuclear hematology deals with the use of radionuclides 5.10 Some Essential Hematopoietic Nutrients 101 or radiopharmaceutical agents in the study of the path- 5.11 Iron Metabolism and Erythropoiesis 101 ophysiology, diagnosis and therapy of hematological 5.12 Intracellular Regulation of Iron 103 diseases arising de novo in the hematopoietic tissues or 5.13 Investigations to Evaluate the Qualitative and as a consequence of some systemic diseases. This prac- Quantitative Aspects of Erythropoiesis 103 tice virtually began in 1940, when John Lawrence first 32 5.14 Iron Absorption 104 used P to treat a young patient with chronic myeloid 32 5.15 Ferrokinetics 104 leukemia [1]. This was followed by the use of Pasara- 5.15.1 Plasma Iron Clearance 105 dioactive label for red cells to measure blood volume 5.15.2 Plasma Iron Turnover 106 [2]. From these modest beginnings, nuclear hematolo- 5.16 Red Cell Utilization (RCU) of Radio-iron 106 gy has come a long way and evolved into a contempo- 5.17 Erythrocyte Iron Turnover 107 rary discipline as a very useful and often an essential investigative tool in many areas of hematology. Radio- 5.18 SurfaceCountsfor59Fe 107 5.19 nuclides are now widely used to label the formed ele- Imaging of Bone Marrow and Other Organs for ments of the blood (random labels) to trace their bio- Evidence of Erythropoietic Activity 108 logical distribution, function and life span in vivo as 5.20 TheLifeSpansofRedBloodCells 109 well as to study the proliferation and differentiation of 5.21 SurfaceCountstoDetermineSitesofRedCell hematopoietic progenitor and precursor cells in the Destruction Using 51Cr-Labeled Red Cells 112 bone marrow (cohort labels). The other major applica- 5.22 Use of Radionuclides in the Investigation of tions of nuclear hematology include the determination Patients with Megaloblastic Anemia 113 5.22.1 Etiopathogenetic Basis of Megaloblastic Anemia 113 of spleen size, splenic sequestration of blood cells and investigations relating to the absorption, metabolism 5.23 Vitamin B12 Radioassay 119 and utilization of hematopoietic nutrients such as iron, 5.24 Determination of Holo-Transcobalmin-II vitamin B and folate. (Holo-TC-II) 119 12 Many imaging techniques are being increasingly 5.25 Identification of the Cause of Vitamin B12 Deficiency 119 employed and explored in order to determine the ana- tomical distribution of hematopoietic tissues in the 5.25.1 Food Cobalamin (Vitamin B12)Malabsorption 120 5.25.2 DNA Synthesis and Deoxyuridine (dU) bone marrow and other organs, and to evaluate their Suppression Test in Megaloblastic Anemia 120 significance in the diagnosis and management of vari- 5.25.3 Deoxyuridine (dU) Suppression Test 121 ous hematological disorders. This chapter reviews the 5.26 Visualization and Imaging of the Spleen in Health pathophysiological basis of the important applications and Disease 122 of radiopharmaceuticals and radio-isotopes in the 5.26.1 Measurement of Splenic Activity 125 practice of hematology. 5.2 Hematopoiesis and Hematopoietic Tissues 91 5.2 tion. A dynamic equilibrium is maintained between Hematopoiesis and Hematopoietic Tissues cell death in peripheral circulation and compensatory production of these cells in the bone marrow, creating Hematopoiesis is a complex biological process which a steady state of “normal blood cell numbers” in physi- represents a unique paradigm of developmental biolo- ological conditions. gy and ontogeny in a replicating mesenchymal cell sys- The circulating blood cells, i.e., the red blood cells, tem – the hematopoietic system. The various blood leukocytes and platelets, are highly specialized cells cells develop from the stem cells by multiplication, dif- with distinctive morphology (structures) and func- ferentiation, orderly maturation and release of mature tions. They are end-stage cells of their respective line- cells from the bone marrow to the peripheral circula- ages and are destined to be lost from the circulation a b cd Fig. 5.1. a Neutrophilic polymorphonuclear leukocytes showing predominantly secondary or specific granules, which are fine and neither basophilic nor eosinophilic (neutral). Romanovsky stain. b Eosinophil, which is a polymorphonuclear leukocyte con- taining large eosinophilic prominent granules in the cytoplasm. Romanovsky stain. c Basophils, which are granulocytic leuko- cytes containing dark colored (basophilic) granules in the cytoplasm. Romanovsky stain. d Electron microscopic picture of an eosinophil showing a large number of intracytoplasmic granules containing electron dense crystaloid cores surrounded by lig- hter areas of matrix 92 5 Nuclear Hematology after a relatively brief time span of hours, days or plasm. The monocytes and all of these granulocytes weeks.Asteadystateisattained,however,andthe have variable degrees of phagocytic function. physiological range of their numbers is maintained by The mature neutrophils (Fig. 5.1a) contain several acontinuoussupplyofnewlyformedcells(regenera- types of granules and other subcellular organelles. tion) from the blood-forming (hematopoietic) tissues. These include the primary or azurophilic granules and The red blood cells (matureerythrocytes),eachap- specific granules.Theprimary granules appear at the proximately 8 µm in diameter, contain hemoglobin in a promyelocytic stage, gradually decrease as the cells reduced (ferrous) state for successful gaseous exchange mature and contain many antimicrobial compounds in the tissues. They circulate in the vascular system as which include myeloperoxidase, defensins, lysozyme, flexible biconcave discs maintaining osmotic equilibri- bactericidal permeability-increasing protein (BPI) and um against high intracellular hemoglobin concentra- several serine proteases such as elastase, cathepsin G, tion and differential concentration gradients of intra- proteinase 3 and others. The primary granules also and extracellular potassium and sodium. The energy contain organelles such as lysosomes, which fuse with required for this physicochemical stability is provided phagocytic vesicles and deliver antimicrobial contents by ATP generated by the anaerobic glycolytic (Emb- to the ingested organisms. Specific granules also called den-Meyerhoff) pathway and the hexose-monophos- secondary granules of the neutrophils may fuse with phate shunt pathway generating reduced coenzymes phagocytic vesicles in inflammatory processes. The NADH and NADPH respectively. contents of these granules include lactoferrin, vitamin- Thematureleukocytes(whitebloodcells)comprise B12-binding proteins (transcobalamins I and III), plas- two broad groups: the granulocytes and monocytes minogen activator, collagenase, etc. These granules al- (phagocytes), and the lymphocytes (immunocytes). so play an important part in promoting chemotaxis and Normally only the mature leukocytes are found in the antimicrobial activities. The main functions of neutro- circulating peripheral blood. These include mature phils consist in their mounting a protective response of granulocytes (neutrophilic polymorphonuclear leuko- the host to microbial infections. The neutrophils ad- cytes, eosinophils and basophils) (Fig. 5.1a–c), mono- here to the endothelial cells (marginate) and then ex- cytes (Fig. 5.2a,b) and lymphocytes (Fig. 5.3a,b). Both tend their cytoplasmic membrane (pseudopodia) into granulocytes and monocytes have phagocytic func- the endothelial cells lining the capillaries and thus emi- tions. With Romanovsky stain, polymorphonuclear grateintothetissuesatthesiteofinfection;theenergy neutrophils show faint, but fine granules (neutral) for this movement is generated by the activation of an- (Fig. 5.1a), eosinophils show larger spherical red or aerobic glycolysis in the granulocytes. The plasma pink granules (Fig. 5.1b), whereas basophils show membrane of the involved neutrophils envelops the in- many dark-staining granules (Fig. 5.1c) in their cyto- vading organisms or particles by its pseudopodia, ab Fig. 5.2a,b. Monocyte; these are generally larger than neutrophils, have delicate fine nuclear chromatin, indistinct nucleoli and thin membrane outline. The cytoplasm is abundant with irregular outline, light blue color and a ground glass appearance 5.2 Hematopoiesis and Hematopoietic Tissues 93 a b Fig. 5.3. a B-lymphocyte, which is a relatively small round mononuclear cell (8–10 µm in diameter), a nucleus occupying almost the whole of the cell usually with no nuclei, and a scanty cytoplasm with a bluish or moderately basophilic narrow rim of cytoplasm. b T-lymphocyte, which contains a dense, but uneven prominent chromatin structure with a shallow intranuclear indentation which fuse around the organisms (phagocytosis) form- entering the tissues. The dark cytoplasmic granules of ing phagosomes. The phagosomes fuse with the con- basophils contain heparin, histamine and minor quan- tents of the azurophilic (primary) and specific (second- tities of other biogenic amines.
Recommended publications
  • 1. Introduction and Literature Review
    1. Introduction and literature review 1.1 Introduction 1.1.1 Defintion of blood Blood is described as a specialized connective tissue,which circulates in a closed system of blood vessels. (Monica.C, 2009) 1.1.2 Blood components Plasma is 55% of the total blood ,plasma cosist of albumin,globulin,water,electrolyte and many other organic and inorganic substances. (Monica.C, 2009) Blood cells is 45% of total blood and encompass;White blood cells(WBCs),Red blood cells(RBCs),and Platelets(Plts). (Monica.C, 2009) 1.1.3 Function of blood -Respiration: transport of oxygen from the lung to tissues and carbon dioxide from tissues to the lungs. -Excreation:transport of metabolic waste to the lungs,kidneys,skin and intestine for removal. - Maintain of normal acid –base balance. -Nutrition of body . -Part of immune system. (Monica.C, 2009) 1 1.1.4 Haemopoiesis Is the general aspect of blood cells formation. (Monica.C, 2009) Haemopoiesis occurs at different anatomical sites the course of development from embryonic life to adult life this site is, up to 2 month of gestation.The haemopoiesis occurs in yolk sac of the embryo.This period called (Myeloblastic period). (Monica.C, 2009) 2-7 month of gestation, this period called (Haepatic period). (Monica.C, 2009) Only important site of all hemopoiesis site after birth,an exception is lymphocyte production which occur in other organ in addition to the bone marrow.This period called(Myeloid period). (Monica.C, 2009) 1.1.5 Development of haemopoiesis The general most commonly accepted view is that blood cells development from small population of stem cells.
    [Show full text]
  • Differentiation of Pluripotent Cells Differenzierung Pluripotenter Zellen Différenciation De Cellules Pluripotentes
    (19) TZZ Z_¥_T (11) EP 2 401 364 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 5/0781 (2010.01) C12N 5/071 (2010.01) 22.04.2015 Bulletin 2015/17 (86) International application number: (21) Application number: 10707179.7 PCT/US2010/025776 (22) Date of filing: 01.03.2010 (87) International publication number: WO 2010/099539 (02.09.2010 Gazette 2010/35) (54) DIFFERENTIATION OF PLURIPOTENT CELLS DIFFERENZIERUNG PLURIPOTENTER ZELLEN DIFFÉRENCIATION DE CELLULES PLURIPOTENTES (84) Designated Contracting States: • WANG LISHENG ET AL: "Endothelial and AT BE BG CH CY CZ DE DK EE ES FI FR GB GR hematopoietic cell fate of human embryonic stem HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL cells originates from primitive endothelium with PT RO SE SI SK SM TR hemangioblastic properties" IMMUNITY, CELL PRESS, US LNKD- DOI:10.1016/J.IMMUNI. (30) Priority: 27.02.2009 US 156304 P 2004.06.006, vol. 21, no. 1, 1 July 2004 (2004-07-01), pages 31-41, XP002484358 ISSN: (43) Date of publication of application: 1074-7613 04.01.2012 Bulletin 2012/01 • BHATIA MICKIE: "Hematopoiesis from human embryonic stem cells." ANNALS OF THE NEW (73) Proprietor: Cellular Dynamics International, Inc. YORK ACADEMY OF SCIENCES JUN 2007 LNKD- Madison, WI 53711 (US) PUBMED:17332088, vol. 1106, June 2007 (2007-06), pages 219-222, XP007912752 ISSN: (72) Inventors: 0077-8923 • RAJESH, Deepika • KENNEDY MARION ET AL: "Development of the Madison, WI 53711 (US) hemangioblast defines the onset of • LEWIS, Rachel hematopoiesis in human ES cell differentiation Madison, WI 53711 (US) cultures" BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol.
    [Show full text]
  • An Introduction to Stem Cell Biology
    An Introduction to Stem Cell Biology Michael L. Shelanski, MD,PhD Professor of Pathology and Cell Biology Columbia University Figures adapted from ISSCR. Presentations of Drs. Martin Pera (Monash University), Dr.Susan Kadereit, Children’s Hospital, Boston and Dr. Catherine Verfaillie, University of Minnesota Science 1999, 283: 534-537 PNAS 1999, 96: 14482-14486 Turning Blood into Brain: Cells Bearing Neuronal Antigens Generated in Vitro from Bone Marrow Science 2000, 290:1779-1782 From Marrow to Brain: Expression of Neuronal Phenotypes in Adult Mice Mezey, E., Chandross, K.J., Harta, G., Maki, R.A., McKercher, S.R. Science 2000, 290:1775-1779 Brazelton, T.R., Rossi, F.M., Keshet, G.I., Blau, H.M. Nature 2001, 410:701-705 Nat Med 2000, 11: 1229-1234 Stem Cell FAQs Do you need to get one from an egg? Must you sacrifice an Embryo? What is an ES cell? What about adult stem cells or cord blood stem cells Why can’t this work be done in animals? Are “cures” on the horizon? Will this lead to human cloning – human spare parts factories? Are we going to make a Frankenstein? What is a stem cell? A primitive cell which can either self renew (reproduce itself) or give rise to more specialised cell types The stem cell is the ancestor at the top of the family tree of related cell types. One blood stem cell gives rise to red cells, white cells and platelets Stem Cells Vary in their Developmental capacity A multipotent cell can give rise to several types of mature cell A pluripotent cell can give rise to all types of adult tissue cells plus extraembryonic tissue: cells which support embryonic development A totipotent cell can give rise to a new individual given appropriate maternal support The Fertilized Egg The “Ultimate” Stem Cell – the Newly Fertilized Egg (one Cell) will give rise to all the cells and tissues of the adult animal.
    [Show full text]
  • Stem Cell Therapy for Neurodegenerative Diseases
    Review Stem Cell Therapy for Neurodegenerative Diseases Hanyang Med Rev 2015;35:229-235 http://dx.doi.org/10.7599/hmr.2015.35.4.229 1 2,3 2,3 pISSN 1738-429X eISSN 2234-4446 Jong Zin Yee , Ki-Wook Oh , Seung Hyun Kim 1Hanyang University College of Medicine, Seoul, Korea 2Department of Neurology, Hanyang University College of Medicine, Seoul, Korea 3Cell Therapy Center for Neurologic Disorders, Hanyang University Hospital, Seoul, Korea Neurodegenerative diseases are the hereditary and sporadic conditions which are charac- Correspondence to: Seung Hyun Kim Department of Neurology, Hanyang terized by progressive neuronal degeneration. Neurodegenerative diseases are emerging University College of Medicine, as the leading cause of death, disabilities, and a socioeconomic burden due to an increase 222 Wangsimni-ro, Seongdong-gu, in life expectancy. There are many neurodegenerative diseases including Alzheimer’s dis- Seoul 04763, Korea Tel: +82-2-2290-8371 ease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and multiple Fax: +82-2-2296-8370 sclerosis, but we have no effective treatments or cures to halt the progression of any of E-mail: [email protected] these diseases. Stem cell-based therapy has become the alternative option to treat neuro- degenerative diseases. There are several types of stem cells utilized; embryonic stem cells, Received 4 September 2015 Revised 6 October 2015 induced pluripotent stem cells, and adult stem cell (mesenchymal stem cells and neural Accepted 13 October 2015 progenitor cells). In this review, we summarize recent advances in the treatments and the This is an Open Access article distributed under limitations of various stem cell technologies.
    [Show full text]
  • Stem Cell Differentiation Investigation • 1 C L a S S S E S S I O N
    14 Stem Cell Differentiation investigation • 1 c l a s s s e s s i o n Overview BaCKgrOund infOrMatiOn To investigate how embryonic stem cells become specialized Stem cells and precursors cells cells, students draw from a set of colored chips that represent A stem call produces daughter cells that might remain as specific molecular factors that determine the next step of stem cells or begin a pathway of differentiation into one of a specialization. They discuss the paths stem cells take as they variety of specialized cell types. Stem cells are classified into differentiate into specialized cells. three groups, depending on where they are on the pathway toward differentiation. Totipotent stem cells can produce any Key COntent kind of cell in the body, and have an unlimited ability to self- renew. The embryonic cells that form during the first few 1. Stem cells can produce a variety of specialized cells. divisions after an egg is fertilized are totipotent. Pluripotent 2. The process by which stem cells produce specialized stem cells can become almost any type of cell in the body, descendent cells is called differentiation. except the cells of the placenta and certain other uterine tis- sues. Totipotent stem cells become pluripotent after three or Materials and advanCe PreParatiOn four divisions. Multipotent stem cells produce only certain For the teacher types of cells. For example, one line of multipotent stem cells Transparency 14.1, “The Organization of Multicellular gives rise to all the blood cells, including red and white blood Organisms” cells. Adult stem cells are multipotent.
    [Show full text]
  • The Possible Role of Mutated Endothelial Cells in Myeloproliferative Neoplasms by Mirko Farina, Domenico Russo, and Ronald Hoffman
    The possible role of mutated endothelial cells in myeloproliferative neoplasms by Mirko Farina, Domenico Russo, and Ronald Hoffman Received: February 17, 2021. Accepted: June 28, 2021. Citation: Mirko Farina, Domenico Russo, and Ronald Hoffman. The possible role of mutated endothelial cells in myeloproliferative neoplasms. Haematologica. 2021 Jul 29. doi: 10.3324/ haematol.2021.278499. [Epub ahead of print] Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process. REVIEW ARTICLE The possible role of mutated endothelial cells in myeloproliferative neoplasms Ferrata Storti Foundation Mirko Farina,1 Domenico Russo1 and Ronald Hoffman2 1Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy and 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA ABSTRACT yeloproliferative neoplasms (MPN) are chronic, clonal hemato- logic malignancies characterized by myeloproliferation and a Mhigh incidence of vascular complications (thrombotic and bleeding).
    [Show full text]
  • Stem Cell Therapy for Movement Disorders
    Parkinsonism and Related Disorders 20S1 (2014) S128–S131 Contents lists available at SciVerse ScienceDirect Parkinsonism and Related Disorders journal homepage: www.elsevier.com/locate/parkreldis The promises of stem cells: stem cell therapy for movement disorders Hideki Mochizuki*, Chi-Jing Choong, Toru Yasuda Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan article info summary Keywords: Despite the multitude of intensive research, the exact pathophysiological mechanisms underlying Stem cell movement disorders including Parkinson’s disease, multiple system atrophy and Huntington’s disease Movement disorders remain more or less elusive. Treatments to halt these disease progressions are currently unavailable. Parkinson’s disease With the recent induced pluripotent stem cells breakthrough and accomplishment, stem cell research, as Induced pluripotent stem cell the vast majority of scientists agree, holds great promise for relieving and treating debilitating movement disorders. As stem cells are the precursors of all cells in the human body, an understanding of the molecular mechanisms that govern how they develop and work would provide us many fundamental insights into human biology of health and disease. Moreover, stem-cell-derived neurons may be a renewable source of replacement cells for damaged neurons in movement disorders. While stem cells show potential for regenerative medicine, their use as tools for research and drug testing is thought to have more immediate impact. The use of stem-cell-based drug screening technology could be a big boost in drug discovery for these movement disorders. Particular attention should also be given to the involvement of neural stem cells in adult neurogenesis so as to encourage its development as a therapeutic option.
    [Show full text]
  • In Viva Growth Factor Expansion of Endogenous Subependymal Neural Precursor Cell Populations in the Adult Mouse Brain
    The Journal of Neuroscience, April 15, 1996, 16(8):2649-2658 In Viva Growth Factor Expansion of Endogenous Subependymal Neural Precursor Cell Populations in the Adult Mouse Brain Constance G. Craig,’ Vince Tropepe,’ Cindi M. Morshead,’ Brent A. Reynolds,2 Samuel Weiss,’ and Derek van der Kooyl 1Neurobiology Research Group, Department of Ana tomy and Cell Biology, University of Toron to, Toronto, Ontario, Canada M5S lA8, and 2Departments of Anatomy and Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada T2N 4NI The lateral ventricle subependyma in the adult mammalian entiated into new astrocytes and 3% into new neurons in the forebrain contains both neural stem and progenitor cells. This cortex, striatum, and septum. Newly generated oligodendro- study describes the in situ modulation of these subependymal cytes were also observed. These in viva results (1) confirm the neural precursor populations after intraventricular administra- existence of EGF-responsive subependymal neural precursor tion of exogenous growth factors. In viva infusion of epidermal cells in the adult mouse forebrain and (2) suggest that EGF acts growth factor (EGF) into adult mouse forebrain for 6 consecu- directly as a proliferation, survival, and migration factor for tive days resulted in a dramatic increase in the proliferation and subependymal precursor cells to expand these populations total number of subependymal cells and induced their migra- and promote the movement of these cells into normal brain tion away from the lateral ventricle walls into adjacent paren- parenchyma. Thus, in situ modulation of endogenous forebrain chyma. Immediately after EGF infusion, immunohistochemical precursor cells represents a novel model for studying neural characterization of the EGF-expanded cell population demon- development in the adult mammalian brain and may provide strated that >95% of these cells were EGF receptor- and insights that will achieve adult replacement of neurons and glia nestin-positive, whereas only 0.9% and 0.2% labeled for as- lost to disease or trauma.
    [Show full text]
  • Hematopoiesis
    UKRAINIAN MEDICAL STOMATOLOGICAL ACADEMY Department of Histology, Cytology and Embryology Hematopoiesis PhD, Teacher of Department of Histology, Cytology and Embryology Skotarenko Tetiana Plan of lecture 1. General characteristics of the organs of hematopoiesis. 2. Embryonic hematopoiesis. 3. Postembryonic hematopoiesis. 4. The modern theory of hematopoiesis. 5. Stem cells. 6. Characterization of cells of all classes of hematopoiesis. 2 Hematopoiesis is development of the blood cells. Mature blood cells have a relatively short life span, and the population must be replaced by the progeny of stem cells produced in the hematopoietic organs. Types of hematopoiesis ► embryonic (prenatal) hematopoiesis which occurs in embryonic life and results in development of a blood as tissue, ► postembryonic (postnatal) hematopoiesis which represents process of physiological regeneration of a blood. Development of erythrocytes name an erythropoiesis, of granulocytes – granulopoiesis, of thrombocytes - thrombopoiesis, of monocytes - monopoiesis, of lymphocytes and immunocytes - lympho- and immunopoiesis. ► In the prenatal period the hematopoiesis serially occurs in several developing organs. ► After birth the hematopoiesis occurs in the bone marrow of a skull, ribs, sternum, pelvic bones, epiphysises of the lengthy bones. Prenatal hematopoiesis 1. The primary (megaloblastic) stage. During 2-3 weeks of development in the wall of the yolk sac the clumps of mesenchymal cells - blood islands - are formed. Prenatal hematopoiesis 1. The primary (megaloblastic) stage Cells on periphery of each island form the endothelium of primary blood vessels. The cells of the central part of an island form the first blood cells - primary erythroblasts - the large cells containing a nucleus and embryonic Hb. Prenatal hematopoiesis 1. The primary (megaloblastic) stage ► Leucocytes and thrombocytes at this stage are not present.
    [Show full text]
  • The Prognostic Significance of Hematogones and CD34+ Myeloblasts in Bone Marrow for Adult B-Cell Lymphoblastic Leukemia Without
    www.nature.com/scientificreports OPEN The prognostic signifcance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease Hongyan Liao1,3, Qin Zheng1,3, Yongmei Jin1, Tashi Chozom2, Ying Zhu1, Li Liu1 & Nenggang Jiang1* This study was aimed to dissect the prognostic signifcances of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell acute lymphoblastic leukemia(ALL) without minimal residual disease(MRD) after the induction chemotherapy cycle. A total of 113 ALL patients who have received standardized chemotherapy cycle were analyzed. Cases that were not remission after induction chemotherapy or have received stem cell transplantation were excluded. Flow cytometry was used to quantify the levels of hematogones and CD34+ myeloblasts in bone marrow aspirations, and the patients were grouped according to the levels of these two precursor cell types. The long-term relapse- free survival(RFS) and recovery of peripheral blood cells of each group after induction chemotherapy were compared. The results indicated that, after induction chemotherapy, patients with hematogones ≥0.1% have a signifcantly longer remission period than patients with hematogones <0.1% (p = 0.001). Meanwhile, the level of hematogones was positively associated with the recovery of both hemoglobin and platelet in peripheral blood, while CD34+ myeloblasts level is irrelevant to the recovery of Hb and PLT in peripheral blood, level of hematogones and long-term prognosis. This study confrmed hematogones level after induction chemotherapy can be used as a prognostic factor for ALL without MRD. It is more applicable for evaluation prognosis than CD34+ myeloblasts. B-cell acute lymphoblastic leukemia (ALL) is a common type of malignant tumor of the hematological system1.
    [Show full text]
  • Why Are Hematopoietic Stem Cells So ‘Sexy’? on a Search for Developmental Explanation
    OPEN Leukemia (2017) 31, 1671–1677 www.nature.com/leu REVIEW Why are hematopoietic stem cells so ‘sexy’? on a search for developmental explanation MZ Ratajczak1,2 Evidence has accumulated that normal human and murine hematopoietic stem cells express several functional pituitary and gonadal sex hormones, and that, in fact, some sex hormones, such as androgens, have been employed for many years to stimulate hematopoiesis in patients with bone marrow aplasia. Interestingly, sex hormone receptors are also expressed by leukemic cell lines and blasts. In this review, I will discuss the emerging question of why hematopoietic cells express these receptors. A tempting hypothetical explanation for this phenomenon is that hematopoietic stem cells are related to subpopulation of migrating primordial germ cells. To support of this notion, the anatomical sites of origin of primitive and definitive hematopoiesis during embryonic development are tightly connected with the migratory route of primordial germ cells: from the proximal epiblast to the extraembryonic endoderm at the bottom of the yolk sac and then back to the embryo proper via the primitive streak to the aorta-gonado-mesonephros (AGM) region on the way to the genital ridges. The migration of these cells overlaps with the emergence of primitive hematopoiesis in the blood islands at the bottom of the yolk sac, and definitive hematopoiesis that occurs in hemogenic endothelium in the embryonic dorsal aorta in AGM region. Leukemia (2017) 31, 1671–1677; doi:10.1038/leu.2017.148 INTRODUCTION the quest for the most primitive HSCs still continues, and several 13,14 There are still two major unknowns that have not been fully potential candidates have been proposed.
    [Show full text]
  • Bone Marrow: General Considerations
    BONE MARROW: 1 GENERAL CONSIDERATIONS The assessment for a possible bone marrow exceeding one billion per kilogram per day for (BM) neoplasm typically begins with a review life. As expected, exquisite regulation of cell of the complete blood count (CBC) and the production is required via the coordinated inter- peripheral blood smear. Such an assessment is play of promotional and inhibitory cytokines, based on a knowledge of normal blood and BM largely created by the progeny of mesenchymal parameters, normal hematopoiesis, and normal stem cells such as fbroblasts, endothelial cells, BM architecture in terms of all hematolymphoid osteoblasts, and adipose cells (Table 1-1; fg. lineages, BM stroma, and bony trabeculae. Also 1-1) (1–14). required is at least a basic understanding of Hematopoietic stem cells are recruited to regulatory factors, including transcriptional specialized loci by mesenchymal cells as well regulators, cell surface receptors, growth factors, as the products of mesenchymal cells. These and other cytokines and receptors (1). hematopoietic stem cell niches are highly pro- The BM is the site of the massive produc- tected sites in which various regulatory factors tion of erythrocytes, platelets, and neutrophils, impact stem cell proliferation and maturation Table 1-1 OVERVIEW OF HEMATOPOIESISa BMb Microenvironmental Niches Mesenchymal stem cells – asymmetric cell division with self-renewal and multilineage mesodermal maturation (osteoblasts, fbroblasts, chondrocytes, endothelial cells, adipocytes) Bony trabeculae lined by
    [Show full text]